Lexicon Pharmaceuticals shares were 21% lower, at $1.14, after the company priced its underwritten public offering of 32 million shares at $1.30 a share. All of the shares are being offered by Lexicon ...

The public offering is expected to close on or about February 2, 2026, subject to the satisfaction of customary closing conditions. In addition, Lexicon has granted the underwriters a 30-day option to ...

THE WOODLANDS, Texas, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“Lexicon ”) today announced that it has commenced an underwritten public offering to offer and ...

Lexicon Inc., a Little Rock-based construction management and steel fabrication company, said Thursday it has become a private, employee-owned company. Lexicon said the decision comes after a ...

Ex-Defense chief Panetta says he doesn’t ‘think there’s any question’ second strike was war crime AccuWeather's 2025-2026 winter forecast Bitcoin Rout Picks Up Steam as Investors Fret Over a New ...

A town's major shopping centre has reportedly been bought by an investment firm for about £150m. US-based Realty Income bought The Lexicon in Bracknell from previous owners Schroder Capital UK Real ...

LITTLE ROCK, AR (KATV) — Lexicon University marked a milestone this morning by graduating its largest class since its inception in 2022. A total of 40 men and women earned welding and industrial ...

Lexicon Pharmaceuticals , Inc. (NASDAQ:LXRX) announced Thursday it has received a letter from the Nasdaq Stock Market granting the company an additional 180-day period, until December 30, 2025, to ...

THE WOODLANDS, Texas, April 02, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a presentation at the 24th Annual ...

March 28 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab is licensing Lexicon Pharmaceuticals' (LXRX.O), opens new tab experimental obesity drug in a deal worth up to $1 billion, the Danish ...

Shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) climbed ~95% in the premarket trading on Friday after the Texas-based biotech announced an exclusive license agreement with Novo Nordisk (NVO) ...